1. Home
  2. JFU vs ACRV Comparison

JFU vs ACRV Comparison

Compare JFU & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 9F Inc.

JFU

9F Inc.

N/A

Current Price

$3.88

Market Cap

54.5M

Sector

Finance

ML Signal

N/A

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

N/A

Current Price

$1.59

Market Cap

52.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JFU
ACRV
Founded
2006
2018
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.5M
52.4M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
JFU
ACRV
Price
$3.88
$1.59
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$13.00
AVG Volume (30 Days)
2.0K
858.0K
Earning Date
12-09-2022
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$691.78
P/E Ratio
$1.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$1.05
52 Week High
$9.48
$5.62

Technical Indicators

Market Signals
Indicator
JFU
ACRV
Relative Strength Index (RSI) 34.98 45.90
Support Level $1.39 $1.57
Resistance Level $4.91 $1.86
Average True Range (ATR) 0.18 0.10
MACD -0.04 0.01
Stochastic Oscillator 0.36 32.00

Price Performance

Historical Comparison
JFU
ACRV

About JFU 9F Inc.

9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: